Plasma protease C1 inhibitor (391-400) Heavy

Ref. 3D-CRB1301339

Informations sur le produit

• Nom: Plasma protease C1 inhibitor (391-400) Heavy
• Synonymes: H-FQPTLLTL^PR-OH

Description

Plasma protease C1 inhibitor (C1-INH) belongs to the serine proteinase inhibitor (serpin) family and is the major regulator of several serine proteases of the human complement, contact and coagulation system. C1-INH contributes to the cross-linking between the complement system, contact system, coagulation, and fibrinolysis. C1-INH can inhibit the initial activation of the complement system via three different pathways: the classical pathway (CP)- the lectin pathway (LP)- and the alternative pathway (AP). C1-INH, therefore suppresses the consequences of complement activation, such as the generation of pro-inflammatory anaphylatoxins, and the formation of a membrane attack complex (MAC) that lyses foreign cells. C1-INH is also the primary regulator of the contact system by inactivating the contact system / intrinsic coagulation proteases plasma kallikrein, factor XIIa (FXIIa), and factor XIa (FXIa), and regulating the generation of bradykinin. C1-INH also exhibits inhibitory effects on other proteases including thrombin, plasmin, and tissue plasminogen activator.C1-INH is associated with various diseases including hereditary and acquired angioedema (HAE, AAE) and age-related macular degeneration (AMD). C1-INH replacement therapy is used to treat HAE. The serum levels of C1-INH, may offer a biomarker for detection of early breast cancer. The leucine residue at position 8 of this peptide is isotopically labelled with carbon-13 (6) and nitrogen-15 (1), giving this peptide a mass increase of 7 compared to the unlabelled peptide.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 1,191.7 g/mol
• Degré de pureté: Min. 95%